Literature DB >> 25098291

The immunotherapeutic role of regulatory T cells in Leishmania (Viannia) panamensis infection.

Allison Ehrlich1, Tiago Moreno Castilho1, Karen Goldsmith-Pestana1, Wook-Jin Chae2, Alfred L M Bothwell2, Tim Sparwasser3, Diane McMahon-Pratt4.   

Abstract

Leishmania (Viannia) parasites are etiological agents of cutaneous leishmaniasis in the New World. Infection is characterized by a mixed Th1/Th2 inflammatory response, which contributes to disease pathology. However, the role of regulatory T cells (Tregs) in Leishmania (Viannia) disease pathogenesis is unclear. Using the mouse model of chronic L. (V.) panamensis infection, we examined the hypothesis that Treg functionality contributes to control of pathogenesis. Upon infection, Tregs (CD4(+)Foxp3(+)) presented with a dysregulated phenotype, in that they produced IFN-γ, expressed Tbet, and had a reduced ability to suppress T cell proliferation in vitro. Targeted ablation of Tregs resulted in enlarged lesions, increased parasite load, and enhanced production of IL-17 and IFN-γ, with no change in IL-10 and IL-13 levels. This indicated that an increased inflammatory response was commensurate with disease exacerbation and that the remaining impaired Tregs were important in regulation of disease pathology. Conversely, adoptive transfer of Tregs from naive mice halted disease progression, lowered parasite burden, and reduced cytokine production (IL-10, IL-13, IL-17, IFN-γ). Because Tregs appeared to be important for controlling infection, we hypothesized that their expansion could be used as an immunotherapeutic treatment approach. As a proof of principle, chronically infected mice were treated with rIL-2/anti-IL-2 Ab complex to expand Tregs. Treatment transitorily increased the numbers and percentage of Tregs (draining lymph node, spleen), which resulted in reduced cytokine responses, ameliorated lesions, and reduced parasite load (10(5)-fold). Thus, immunotherapy targeting Tregs could provide an alternate treatment strategy for leishmaniasis caused by Leishmania (Viannia) parasites.
Copyright © 2014 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25098291      PMCID: PMC4170189          DOI: 10.4049/jimmunol.1400728

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  87 in total

1.  Adjuvant effect of diphtheria toxin after mucosal administration in both wild type and diphtheria toxin receptor engineered mouse strains.

Authors:  Timothy J Chapman; Steve N Georas
Journal:  J Immunol Methods       Date:  2013-11-05       Impact factor: 2.303

2.  Decreased in situ expression of interleukin-10 receptor is correlated with the exacerbated inflammatory and cytotoxic responses observed in mucosal leishmaniasis.

Authors:  Daniela R Faria; Kenneth J Gollob; José Barbosa; Albert Schriefer; Paulo R L Machado; Hélio Lessa; Lucas P Carvalho; Marco Aurélio Romano-Silva; Amélia R de Jesus; Edgar M Carvalho; Walderez O Dutra
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

Review 3.  Leishmania and the leishmaniases: a parasite genetic update and advances in taxonomy, epidemiology and pathogenicity in humans.

Authors:  Anne-Laure Bañuls; Mallorie Hide; Franck Prugnolle
Journal:  Adv Parasitol       Date:  2007       Impact factor: 3.870

4.  Cytokine profile and pathology in human leishmaniasis.

Authors:  A Ribeiro-de-Jesus; R P Almeida; H Lessa; O Bacellar; E M Carvalho
Journal:  Braz J Med Biol Res       Date:  1998-01       Impact factor: 2.590

5.  An inherently bifunctional subset of Foxp3+ T helper cells is controlled by the transcription factor eos.

Authors:  Madhav D Sharma; Lei Huang; Jeong-Hyeon Choi; Eun-Joon Lee; James M Wilson; Henrique Lemos; Fan Pan; Bruce R Blazar; Drew M Pardoll; Andrew L Mellor; Huidong Shi; David H Munn
Journal:  Immunity       Date:  2013-05-16       Impact factor: 31.745

6.  Selective stimulation of T cell subsets with antibody-cytokine immune complexes.

Authors:  Onur Boyman; Marek Kovar; Mark P Rubinstein; Charles D Surh; Jonathan Sprent
Journal:  Science       Date:  2006-02-16       Impact factor: 47.728

7.  Pentoxifylline down modulate in vitro T cell responses and attenuate pathology in Leishmania and HTLV-I infections.

Authors:  Amelia Ribeiro de Jesus; Tânia Luna; Roque Pacheco de Almeida; Paulo Roberto Lima Machado; Edgar M Carvalho
Journal:  Int Immunopharmacol       Date:  2008-04-28       Impact factor: 4.932

8.  Regulatory T cells in the pathogenesis and healing of chronic human dermal leishmaniasis caused by Leishmania (Viannia) species.

Authors:  Daniel Rodriguez-Pinto; Adriana Navas; Víctor Manuel Blanco; Lady Ramírez; Daniel Garcerant; Adriana Cruz; Noah Craft; Nancy Gore Saravia
Journal:  PLoS Negl Trop Dis       Date:  2012-04-24

9.  Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease.

Authors:  Katharina Lahl; Christoph Loddenkemper; Cathy Drouin; Jennifer Freyer; Jon Arnason; Gérard Eberl; Alf Hamann; Hermann Wagner; Jochen Huehn; Tim Sparwasser
Journal:  J Exp Med       Date:  2007-01-02       Impact factor: 14.307

10.  Internalization of Leishmania mexicana complex amastigotes via the Fc receptor is required to sustain infection in murine cutaneous leishmaniasis.

Authors:  P E Kima; S L Constant; L Hannum; M Colmenares; K S Lee; A M Haberman; M J Shlomchik; D McMahon-Pratt
Journal:  J Exp Med       Date:  2000-03-20       Impact factor: 14.307

View more
  13 in total

1.  The Src kinases Hck, Fgr and Lyn activate Arg to facilitate IgG-mediated phagocytosis and Leishmania infection.

Authors:  Dawn M Wetzel; Emma L Rhodes; Shaoguang Li; Diane McMahon-Pratt; Anthony J Koleske
Journal:  J Cell Sci       Date:  2016-06-29       Impact factor: 5.285

2.  Immunomodulatory nanoparticles ameliorate disease in the Leishmania (Viannia) panamensis mouse model.

Authors:  Alyssa L Siefert; Allison Ehrlich; María Jesús Corral; Karen Goldsmith-Pestana; Diane McMahon-Pratt; Tarek M Fahmy
Journal:  Biomaterials       Date:  2016-09-06       Impact factor: 12.479

Review 3.  Circulatory microRNAs: promising non-invasive prognostic and diagnostic biomarkers for parasitic infections.

Authors:  Hossein Ghalehnoei; Abouzar Bagheri; Mahdi Fakhar; Mohammad Amir Mishan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-10-15       Impact factor: 3.267

4.  Local Delivery of the Toll-Like Receptor 9 Ligand CpG Downregulates Host Immune and Inflammatory Responses, Ameliorating Established Leishmania (Viannia) panamensis Chronic Infection.

Authors:  Allison K Ehrlich; Olga L Fernández; Daniel Rodriguez-Pinto; Tiago M Castilho; Maria J Corral Caridad; Karen Goldsmith-Pestana; Nancy Gore Saravia; Diane McMahon-Pratt
Journal:  Infect Immun       Date:  2017-02-23       Impact factor: 3.441

5.  A Mouse Model of Ulcerative Cutaneous Leishmaniasis by Leishmania (Viannia) panamensis to Investigate Infection, Pathogenesis, Immunity, and Therapeutics.

Authors:  Natalia Muñoz-Durango; Alexander Gómez; Natalia García-Valencia; Miguel Roldán; Marcela Ochoa; David E Bautista-Erazo; José R Ramírez-Pineda
Journal:  Front Microbiol       Date:  2022-06-13       Impact factor: 6.064

Review 6.  Cutaneous leishmaniasis: immune responses in protection and pathogenesis.

Authors:  Phillip Scott; Fernanda O Novais
Journal:  Nat Rev Immunol       Date:  2016-07-18       Impact factor: 53.106

Review 7.  Deception and manipulation: the arms of leishmania, a successful parasite.

Authors:  Pedro Cecílio; Begoña Pérez-Cabezas; Nuno Santarém; Joana Maciel; Vasco Rodrigues; Anabela Cordeiro da Silva
Journal:  Front Immunol       Date:  2014-10-20       Impact factor: 7.561

Review 8.  Alternative to Chemotherapy-The Unmet Demand against Leishmaniasis.

Authors:  Nicky Didwania; Md Shadab; Abdus Sabur; Nahid Ali
Journal:  Front Immunol       Date:  2017-12-21       Impact factor: 7.561

Review 9.  Cutaneous Leishmaniasis: The Complexity of Host's Effective Immune Response against a Polymorphic Parasitic Disease.

Authors:  Áurea Gabriel; Ana Valério-Bolas; Joana Palma-Marques; Patrícia Mourata-Gonçalves; Pedro Ruas; Tatiana Dias-Guerreiro; Gabriela Santos-Gomes
Journal:  J Immunol Res       Date:  2019-12-01       Impact factor: 4.818

10.  Programmed Cell Death Ligand (PD-L)-1 Contributes to the Regulation of CD4+ T Effector and Regulatory T Cells in Cutaneous Leishmaniasis.

Authors:  Rafael de Freitas E Silva; Rosa Isela Gálvez; Valéria Rego Alves Pereira; Maria Edileuza Felinto de Brito; Siew Ling Choy; Hannelore Lotter; Lidia Bosurgi; Thomas Jacobs
Journal:  Front Immunol       Date:  2020-10-22       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.